We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Chemotherapy Triggers Overexpression of a Drug Resistance Gene

By LabMedica International staff writers
Posted on 11 Feb 2013
Cancer researchers have identified a gene activated by chemotherapy and induce tumor cells to become drug resistant, which inevitably presents a poor prognosis for the patient.

Investigators at the University of Iowa (Iowa City, USA) and Brigham Young University (Provo, UT, USA) initially mapped genetic changes in a sequential series of tumor samples obtained from 19 myeloma patients undergoing intensive chemotherapy.

They reported in the January 14, 2013, issue of the journal Cancer Cell that the gene NEK2 (never in mitosis gene a-related kinase 2), a serine/threonine-protein kinase that is involved in mitotic regulation, was highly correlated with drug resistance, rapid relapse, and poor outcome. This protein is localized to the centrosome and undetectable during G1 phase, but accumulates progressively throughout the S phase, reaching maximal levels in late G2 phase.

Other studies revealed that NEK2 was overexpressed in many different types of cancer. Overexpression of NEK2 resulted in enhanced CIN (chromosomal instability, which occurs early in cancer development and is associated with poor prognosis), cell proliferation, and drug resistance. High expression of NEK2 induced drug resistance mainly through activation of the cancer cells' efflux pumps.

Targeting NEK2 by NEK2 shRNA (short hairpin RNA) overcame cancer cell-drug resistance and induced apoptosis in vitro and in a xenograft myeloma mouse model.

"Our studies show that over-expression of NEK2 in cancer cells significantly enhances the activity of drug efflux proteins to pump chemotherapy drugs out of cells, resulting in drug resistance. Furthermore, silencing NEK2 in cancer cells potently decreased drug resistance, induced cell-cycle arrest, cell death, and inhibited cancer cell growth in vitro and in vivo," said senior author Dr. Fenghuang Zhan, professor of internal medicine at the University of Iowa.

The investigators are now concentrating on the development of compounds to inhibit NEK2 activity.

Related Links:
University of Iowa
Brigham Young University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Thyroid Test
Anti-Thyroid EIA Test
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10

Latest BioResearch News

D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
11 Feb 2013  |   BioResearch

New Genetic Cause Identified for Neurodevelopmental Disorder
11 Feb 2013  |   BioResearch

New Genetic Discovery Could Support Precision Diabetes Care
11 Feb 2013  |   BioResearch